Course Information

Release date: September 4, 2026
Expiration date: December 4, 2026
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This educational activity is supported by a medical education grant from Stemline Therapeutics, Inc.

PROGRAM OVERVIEW

This enduring activity uses a real-world case of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer progressing after first-line aromatase inhibitor (AI) plus cyclin-dependent kinase 4/6 (CDK4/6) inhibition to examine contemporary treatment selection of selective estrogen receptor degraders (SERDs) after acquisition of an ESR1 mutation. Emphasis is placed on repeat molecular testing at progression, interpretation of the phase 3 EMERALD, EMBER-3, and VERITAC-2 trials, and emerging data from trials such as SERENA-6 and evERA. Clinicians will be able to identify practical differences among currently available oral SERDs as well as best practices for tailoring therapy based on patient-specific and disease-specific features.

Learning Objectives

TARGET AUDIENCE

This activity addresses the needs of medical, surgical, and radiation oncologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in the treatment and management of patients with breast cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Select treatment based on genomic, immunogenic, and proteomic biomarkers in breast cancer
Identify personalized therapeutic regimens for specific patients consistent with current evidence guidelines in breast cancer
Optimize supportive care through monitoring and management for unique toxicities associated with breast cancer therapies

Faculty Information and Disclosures

FACULTY

Elizabeth Sakach, MD

Assistant Professor

Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, Georgia

Shalini Vemuru, MD

Fellow

Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, Georgia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Elizabeth Sakach, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

Shalini Vemuru, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 4, 2026 through December 4, 2026, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 4, 2026Expiration date: December 4, 2026 Estimated time to complete activity: 15 minutes

Oral SERDs in HR+/HER2− Advanced Breast Cancer: Applying Emerging Data to Treatment Selection